Journal article icon

Journal article

Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question.

Abstract:

BACKGROUND: Rapid resolution of rectal bleeding and stool frequency are important goals for ulcerative colitis therapy and may help guide therapeutic decisions. AIM: To explore patient diary data from ASCEND I and II for their relevance to clinical decision making. METHODS: Data from two randomised, double-blind, Phase III studies were combined. Patients received mesalazine (mesalamine) 4.8 g/day (Asacol 800 mg MR) or 2.4 g/day (Asacol 400 mg MR). Time to improvement or resolution of rectal ...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Orchard, TR More by this author
van der Geest, SA More by this author
Travis, SP More by this author
Journal:
Alimentary pharmacology and therapeutics
Volume:
33
Issue:
9
Pages:
1028-1035
Publication date:
2011-05-05
DOI:
EISSN:
1365-2036
ISSN:
0269-2813
URN:
uuid:92cdb542-9098-4cfb-9594-e822daed12f8
Source identifiers:
220010
Local pid:
pubs:220010

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP